Overview

Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis

Status:
Completed

Trial end date:
2008-05-27

Target enrollment:

Participant gender:

Summary

This is a randomized open label, multi-centre study for Korean women with postmenopausal osteoporosis, evaluating the preference for either the once-monthly dosing of ibandronate or the once-weekly dosing of risedronate. Eligible subjects will be randomised either ibandronate monthly regimen or risedronate weekly regimen. Treatment period consists of 3 month with ibandronate 150mg and additional 12 week with risedronate 35 mg or vice versa. After taking the first interventional medicine for 3 months or 12 weeks completely, a subject changes the treatment arm. There is no washout period.

Phase:

Phase 4

Details

Lead Sponsor:

GlaxoSmithKline
Hoffmann-La Roche

Treatments:

Diphosphonates
Ibandronic Acid
Risedronate Sodium